TGF-β-dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36229613.
- Also identified by DOI 10.1038/s41467-022-33768-x and PMC identifier 9562983.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
TGF-β signaling is necessary for CD8<sup>+</sup> T cell differentiation into tissue resident memory T cells (T<sub>RM</sub>). Although higher frequency of CD8<sup>+</sup> T<sub>RM</sub> cells in the tumor microenvironment is associated with better prognosis, TGF-β-blockade typically improves rather than worsens outcomes. Here we show that in a mouse melanoma model, in the tumor-draining lymph nodes (TDLN) rather than in the tumors themselves, stem-like CD8<sup>+</sup> T cells differentiate into T<sub>RM</sub>s in a TGF-β and tumor antigen dependent manner. Following vaccination against a melanoma-specific epitope, most tumour-specific CD8<sup>+</sup> T cells are maintained in a stem-like state, but a proportion of cells lost T<sub>RM</sub> status and differentiate into CX3CR1<sup>+</sup> effector CD8<sup>+</sup> T cells in the TDLN, which are subsequently migrating into the tumours. Disruption of TGF-β signaling changes the dynamics of these developmental processes, with the net result of improving effector CD8<sup>+</sup> T cell migration into the tumours. In summary, TDLN stem-like T cells transiently switch from a TGF-β-dependent T<sub>RM</sub> differentiation program to an anti-tumor migratory effector development upon vaccination, which transition can be facilitated by targeted TGF-β blockade.
Medical subject headings
- AIDS Vaccines
- Cancer Vaccines
- Influenza Vaccines
- Melanoma
- Papillomavirus Vaccines
- Respiratory Syncytial Virus Vaccines
- SAIDS Vaccines